Lini Pandite

Lini Pandite, MBChB, is currently Chief Medical Officer at Shattuck Labs. Prior to joining Shattuck Labs, she served as Senior Vice President, Head of Clinical Development at Adaptimmune. Dr. Pandite spent several years with GlaxoSmithKline (GSK) culminating in her tenure as Vice President, Head Unit Physician for Oncology R&D. Her broad oncology drug development expertise spans early-to-late phase development from Pre-IND through marketing authorization and commercialization.

Dr. Pandite practiced medicine in both the United Kingdom and the United States and is Board Certified in Hematology and Oncology. She was an attending physician at Dana Farber Cancer Institute in Boston and at Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital in Miami, and held academic appointments at Harvard University and the University of Miami. Dr. Pandite received an MBChB from The University of Liverpool, England, and an MBA from Duke University.